Chronic Radiation Enteritis: An Empiric Trial for a Diagnosis the Standard Test Can’t Confirm
A single patient, years past the pelvic radiation that cured his cancer, now living with a chronic diarrhea whose exact cause the standard confirmatory test in the U.S. essentially cannot answer. The disagreement is about how much confirmation an empiric trial actually needs.
Harold N., a 70-year-old man, built his retirement around road trips to see his grandchildren scattered across three states, until a chronic diarrhea that followed his pelvic radiation for localized prostate cancer six years ago turned every outing longer than an hour into a restroom-mapping exercise first. He has been cancer-free the whole time since, a trade he has always said he'd make again without hesitation — decades spent as an accountant left him precise enough by habit that he still keeps a symptom log most patients his age wouldn't think to start. Colonoscopy two years ago showed the expected mild chronic radiation changes in the rectum and distal colon but nothing to explain diarrhea of this severity, and repeat imaging has found no recurrent malignancy, no stricture, and no fistula.
His symptom pattern — worse with fat intake, better with fasting — is classically consistent with bile acid malabsorption from radiation injury to his terminal ileum, the segment most exposed during his original treatment field and the segment responsible for reclaiming bile acids before they reach the colon, where unabsorbed bile acids directly stimulate colonic secretion and produce exactly this kind of diarrhea. The complication is that the test built to confirm this diagnosis directly, SeHCAT scanning, has never been approved for use in the United States — it is routine in the United Kingdom and much of Europe and simply unavailable here — leaving American clinicians to reason from pattern and empiric response far more often than the textbook diagnostic sequence would prefer. Cholestyramine, the standard bile acid sequestrant, is not pharmacologically neutral if that reasoning turns out to be wrong — it binds bile acids and fat-soluble vitamins indiscriminately, and starting it in a patient whose diarrhea has a different or additional driver risks compounding rather than correcting his malabsorption. Radiation-injured bowel with altered motility is also a recognized, independent risk factor for small intestinal bacterial overgrowth, raising the real possibility that more than one mechanism is contributing at once, and that treating only the bile-acid component might produce a partial response easily misread as evidence against the diagnosis itself.
GI clinic, chronic radiation enteritis workup
I want to start empiric cholestyramine today. His symptom pattern is about as classic for bile acid malabsorption as this presentation gets, and SeHCAT testing simply isn’t available to us or to any center I could refer him to — it was never approved in this country, so this isn’t a referral problem I can solve. Empiric treatment in exactly this situation, where confirmatory testing is a real access problem rather than a choice, is standard practice, not a shortcut.
I’d want a baseline first — fat-soluble vitamin levels and a stool fat measurement, neither of which requires SeHCAT access. Cholestyramine isn’t a neutral trial-and-see drug; it binds fat-soluble vitamins and additional bile acids indiscriminately, and if his real driver turns out to be something else, or if he already has meaningful steatorrhea from another cause, we could be making his malabsorption worse rather than better.
I’m not asking for SeHCAT — I know it isn’t available. I’m asking for the baseline data we CAN get, specifically because the drug we’re about to start has a real cost if the diagnosis is wrong.
I want to raise a possibility neither of you has named yet: this might not be one problem. Radiation-injured bowel with altered motility is its own recognized risk factor for small intestinal bacterial overgrowth, independent of bile acid malabsorption. If both are present and we only treat the bile-acid piece, we could get a partial response that gets misread as cholestyramine "not really working," when actually it’s working exactly as much as it should for the piece it addresses.
I’d get the baseline labs the pharmacologist wants, add a SIBO breath test at the same visit since it costs him nothing extra to collect, and start cholestyramine once we have both results in hand rather than treating this as necessarily a single-mechanism diagnosis.
Agreed: baseline fat-soluble vitamin panel, stool fat measurement, and a SIBO breath test all ordered at today’s visit; cholestyramine starts once those results are back, rather than today.
Not agreed: if the SIBO breath test comes back positive, whether to treat it first, simultaneously with cholestyramine, or only if cholestyramine alone produces an incomplete response. The primary care physician favors treating both findings together if both are positive; the gastroenterologist would rather isolate the bile-acid-sequestrant effect first before adding a second intervention.